Monte Carlo design study of a moderated 252Cf source for in vivo neutron activation analysis of aluminium.

The Monte Carlo computer code MCNP has been used to design a moderated 252Cf neutron source for in vivo neutron activation analysis of aluminium (Al) in the bones of the hand. The clinical motivation is the need to monitor Al body burden in subjects with renal dysfunction, at risk of Al toxicity. The design involves the source positioned on the central axis at one end of a cylindrical deuterium oxide moderator. The moderator is surrounded by a graphite reflector, with the hand inserted at the end of the moderator opposing the source. For a 1 mg 252Cf source, 15 cm long x 20 cm radius moderator and 20 cm thick reflector, the estimated minimum detection limit is 0.5 mg Al for a 20 min irradiation, with an equivalent dose of 16.5 mSv to the hand. Increasing the moderator length and/or introducing a fast neutron filter (for example silicon) further reduces interference from fast-neutron-induced reactions on phosphorus in bone, at the expense of decreased fluence of the thermal neutrons which activate Al. Increased source strengths may be necessary to compensate for this decreased thermal fluence, to allow measurements to be made within an acceptable time limit for the comfort of the patient.

[1]  M. Wilson,et al.  Design of a californium-based epithermal neutron beam for neutron capture therapy. , 1993, Physics in medicine and biology.

[2]  W. Morgan,et al.  The development of a technique to measure bone aluminium content using neutron activation analysis. , 1993, Physiological measurement.

[3]  S. Green,et al.  A feasibility study of the in vivo measurement of aluminium in peripheral bone. , 1992, Physics in medicine and biology.

[4]  J. Yanch,et al.  Dosimetry of 252Cf sources for neutron radiotherapy with and without augmentation by boron neutron capture therapy. , 1992, Radiation research.

[5]  H. Malluche,et al.  Renal bone disease 1990: an unmet challenge for the nephrologist. , 1990, Kidney international.

[6]  P. Altmann,et al.  DISTURBANCE OF CEREBRAL FUNCTION BY ALUMINIUM IN HAEMODIALYSIS PATIENTS WITHOUT OVERT ALUMINIUM TOXICITY , 1989, The Lancet.

[7]  K. Ellis,et al.  In vivo monitoring of skeletal aluminum burden in patients with renal failure , 1988 .

[8]  W. Morgan,et al.  A clinical instrument for multi-element in vivo analysis by prompt, delayed and cyclic neutron activation using 252Cf. , 1987, Physics in medicine and biology.

[9]  D. Chettle,et al.  Techniques of in vivo neutron activation analysis , 1984, Physics in medicine and biology.

[10]  J. O'hare,et al.  Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. , 1982, The New England journal of medicine.

[11]  E. D. Williams,et al.  Whole body aluminium in chronic renal failure and dialysis encephalopathy. , 1980, Clinical nephrology.

[12]  P. S. Nagarajan,et al.  Neutron dose distributions for californium-252 sources. , 1971, The International journal of applied radiation and isotopes.

[13]  V. Krishaswamy Calculation of the dose distribution about californium-252 needles in tissue. , 1971, Radiology.